XORTX Therapeutics Files Q1 2024 Financial Results
Ticker: XRTX · Form: 6-K · Filed: May 17, 2024 · CIK: 1729214
Sentiment: neutral
Topics: financials, reporting, biotech
TL;DR
XORTX dropped Q1 financials, check 'em out.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on May 17, 2024, reporting its financial results for the three months ended March 31, 2024. The filing includes condensed interim consolidated financial statements and management's discussion and analysis. The company is a foreign private issuer based in Vancouver, Canada, and its CEO is Allen Davidoff.
Why It Matters
This filing provides investors with an update on XORTX Therapeutics' financial performance and operational status for the first quarter of 2024, crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, XORTX faces inherent risks related to drug development, regulatory approvals, and market adoption, which are not fully detailed in this financial reporting form.
Key Numbers
- Q1 2024 — Reporting Period (Financial results for the three months ended March 31, 2024, are presented.)
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- March 31, 2024 (date) — End of reporting period
- May 17, 2024 (date) — Filing date
FAQ
What specific financial figures are detailed in the Condensed Interim Consolidated Financial Statements?
The filing indicates that Exhibit 99.1 contains the Condensed Interim Consolidated Financial Statements for the three months ended March 31, 2024, but the specific figures are not listed in the 6-K header.
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of May 2024, providing financial statements and management discussion.
Who is the Chief Executive Officer of XORTX Therapeutics Inc. and when was this report signed?
Allen Davidoff is the Chief Executive Officer, and the report was signed on May 15, 2024.
What exhibits are included with this Form 6-K filing?
The exhibits include Condensed Interim Consolidated Financial Statements (99.1), Management Discussion and Analysis (99.2), CEO Certificate (99.3), and CFO Certificate (99.4).
What is XORTX Therapeutics Inc.'s fiscal year end?
XORTX Therapeutics Inc.'s fiscal year ends on December 31.
Filing Stats: 161 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-05-16 18:45:31
Filing Documents
- f6k_051524.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 341KB
- exh_992.htm (EX-99.2) — 181KB
- exh_993.htm (EX-99.3) — 10KB
- exh_994.htm (EX-99.4) — 10KB
- logo.jpg (GRAPHIC) — 8KB
- 0001171843-24-002946.txt ( ) — 558KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33 rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX THERAPEUTICS INC. (Registrant) Date: May 15, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 Condensed Interim Consolidated Financial Statements for the three months ended March 31, 2024 99.2 Management Discussion and Analysis for the three months ended March 31, 2024 99.3 CEO Certificate 99.4 CFO Certificate